Cargando…

131. Duration of Therapy for the Treatment of Gram-Negative Bloodstream Infections

BACKGROUND: While current guidelines suggest a total treatment duration of 7 to 14 days for gram-negative bloodstream infections (GN-BSI), there is mounting evidence to suggest that shorter durations may be sufficient. This study compared the treatment outcomes of patients who received short duratio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shulder, Stephanie, O’Connell, Matthew, Agedal, Kaitlyn J, Conn, Kelly M, Pillinger, Kelly E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809877/ http://dx.doi.org/10.1093/ofid/ofz360.206

Ejemplares similares

2421. Efficacy of Secondary Prophylaxis with Oral Vancomycin in Preventing Recurrent Clostridioides difficile Infections in Patients Receiving Systemic Antibiotics
por: Pillinger, Kelly E, et al.
Publicado: (2019)

1815. Assessment of Therapy Duration for Non-Staphylococcal Gram-Positive Bloodstream Infections
por: Gould, Alyssa P, et al.
Publicado: (2022)

198. Comparison of Standard versus Extended Treatment Duration for Gram-negative Bloodstream Infections with Obstructing Nephrolithiasis or Urolithiasis
por: Harpenau, Tara L, et al.
Publicado: (2023)

Epidemiology of Gram-Negative Bloodstream Infections in the United States: Results From a Cohort of 24 Hospitals
por: Ince, Dilek, et al.
Publicado: (2023)

1841. Incidence and Predictors of Complications in Gram Negative Bloodstream Infection
por: Mondal, Utpal, et al.
Publicado: (2022)

217. Broad Spectrum Antibiotic use in Outpatient Parenteral Antibiotic Therapy (OPAT): Opportunities for Antibiotic Stewardship
por: Brenon, Jessa R, et al.
Publicado: (2020)

65. Impact of a Multifaceted Stewardship Intervention on Oral Fosfomycin Prescribing for Treatment of Resistant Organisms in Cystitis
por: Pry, Marie, et al.
Publicado: (2020)

1043. Evaluation of Early Clinical Failure Criteria for Gram-Negative Bloodstream Infections
por: Rac, Hana, et al.
Publicado: (2018)

224. Clinical Relevance of Antibiotic Tolerance in Recurrent Gram-negative Bloodstream Infections
por: Parsons, Joshua B, et al.
Publicado: (2023)

166. Comparison of Oral Fluoroquinolones to Alternative Oral Agents for Definitive Step-Down Therapy in Gram-Negative Bloodstream Infections
por: Cho, Christian Y, et al.
Publicado: (2019)

59. Risk Factors for Recurrent Gram-Negative Bacterial Bloodstream Infections
por: Bock, Andrew J, et al.
Publicado: (2021)

254. Genomic diversity of Gram-negative Bacilli from Bloodstream Infections in Hospitalized Children
por: Blumenthal, Jennifer, et al.
Publicado: (2023)

906. Impact of Accelerate Rapid Diagnostic Technology on Time to Optimal Antimicrobial Therapy in Gram Negative Bloodstream Infection
por: Jung, Hye Lim, et al.
Publicado: (2022)

2174. Comparison of the Verigene® and the ePlex® Blood Culture Identification Panels for Gram-Positive and Gram-Negative Bloodstream Infections
por: Johnson, J Kristie, et al.
Publicado: (2019)

715 Impact of Fluoroquinolone Resistance on Community-Onset Gram-Negative Bloodstream Infections
por: Brigmon, Matthew, et al.
Publicado: (2014)

Gram-Negative Polymicrobial Bloodstream Infections and Clinical Decision Making with a Microarray Testing System
por: Claeys, Kimberly, et al.
Publicado: (2017)

141. Use of Rapid Diagnostic Testing in Gram-negative Bloodstream Infections with and without Antimicrobial Stewardship
por: Claeys, Kimberly C, et al.
Publicado: (2019)

147. Non-Fermenting Gram-Negative Bloodstream Infection: A Multicenter Retrospective Cohort Study
por: Pascale, Renato, et al.
Publicado: (2019)

1010. Effectiveness of Oral Antibiotics for Definitive Therapy of Gram-Positive Bloodstream Infections
por: Roshdy, Danya, et al.
Publicado: (2018)

Survey of infectious diseases providers reveals variability in duration of antibiotic therapy for the treatment of Gram-negative bloodstream infections
por: Thaden, Joshua T., et al.
Publicado: (2022)

2334. Risk Factors of Multidrug-Resistant Gram-Negative Bacterial Bloodstream Infections in Children’s Hospitals in Japan
por: Aizawa, Yuta, et al.
Publicado: (2018)

212. Effectiveness of Empirical Piperacillin/tazobactam Compared to Cefepime for Bloodstream Infection Caused by Gram-Negative Bacilli
por: Ho Lee, Young, et al.
Publicado: (2023)

Procalcitonin Levels in Gram-Positive, Gram-Negative, and Fungal Bloodstream Infections
por: Leli, Christian, et al.
Publicado: (2015)

205. Evaluating the Time to Oral Step-Down Therapy for Gram-Negative Bloodstream Infections Associated with a Genitourinary Source
por: Mulvey, Nicole, et al.
Publicado: (2021)

290. Impact of follow up blood cultures on outcomes of patients with gram-negative bloodstream infections
por: Amipara, Rajiv G, et al.
Publicado: (2020)

Cefepime-Zidebactam (WCK 5222) Activity Tested against Gram-negative Organisms Causing Bloodstream Infections Worldwide
por: Sader, Helio S, et al.
Publicado: (2017)

2163. Risk Factors for Carbapenem-Resistant Gram-Negative Bloodstream Infections (BSI) in U.S. Hospitals (2010–2015)
por: Cai, Bin, et al.
Publicado: (2018)

960. Clinical impact of follow-up blood cultures in gram-negative bloodstream infections: A validation cohort
por: Thaden, Joshua T, et al.
Publicado: (2023)

203. Evaluating the Impact of Extended-Infusion Beta-Lactam Therapy on Clinical Outcomes and the Subsequent Emergence of Resistance in Adults with Gram-Negative Bloodstream Infections
por: Karaba, Sara M, et al.
Publicado: (2023)

487. Prevalence of Antimicrobial Resistance in Gram-Negative Bacilli Bloodstream Infections at a Tertiary Teaching Hospital in the Dominican Republic
por: Mena Lora, Alfredo J, et al.
Publicado: (2019)

Gram-Negative Bloodstream Infection: Implications of Antimicrobial Resistance on Clinical Outcomes and Therapy
por: Al-Hasan, Majdi N.
Publicado: (2020)

222. Bloodstream Infections by Gram(−) Bacteria in Kidney Transplant Patients: Risk Factors, Incidence and Outcome; Bloodstream Infections by Gram(−) Bacteria in Kidney Transplant Patients: Risk Factors, Incidence and Outcome
por: Tsikala Vafea, Maria, et al.
Publicado: (2019)

159. Comparing Clinical Cure and Patient Outcomes Between Intravenous Therapy and Intravenous (IV)-to-Oral (PO) Step-down Therapy for Treatment of Gram-Negative Bloodstream Infections
por: Williams, Kelsey, et al.
Publicado: (2019)

1191. Prevalence and Microbiology of Carbapenem Resistance Among Six Gram-Negative Pathogens in Bloodstream Infections in US Hospitals, 2010–2015
por: Lodise, Thomas P, et al.
Publicado: (2018)

1050. Oral Antibiotics for the Treatment of Gram-Negative Bloodstream Infections: Prescribing Practices and Outcomes at a Large Academic Medical Center
por: Claeys, Kimberly, et al.
Publicado: (2018)

151. Comparing the Clinical Utility of Rapid Diagnostic Tests for Gram-Negative Bloodstream Infection Using a Desirability of Outcomes Ranking
por: Claeys, Kimberly C, et al.
Publicado: (2019)

2454. A Cluster of Gram-Negative Bloodstream Infections in Connecticut Hemodialysis Patients Associated with Contaminated Wall Boxes and Priming Buckets
por: Backman, Lauren, et al.
Publicado: (2019)

2851. Impact of Antimicrobial-Resistant Gram-Negative Bloodstream Infections on Outcomes Among Pediatric Hospitalizations in the United States, 2009–2016
por: Spaulding, Alicen B, et al.
Publicado: (2019)

186. The Role of Repeated Blood Cultures in Hematologic Malignancy Patients with Neutropenic Fever due to Gram-Negative Bacterial Bloodstream Infections
por: Dhanaraj, Nitya, et al.
Publicado: (2023)

150. Urinary Tract-Associated Gram-Negative Bacteremia: Impact of Treatment Duration
por: Badwal, Jasmin K, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a0mk6bctevvnlfcqqek7dn2d8v